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IL-32 Promotes Angiogenesis
Claudia A. Nold-Petry,* Ina Rudloff,* Yvonne Baumer,† Menotti Ruvo,‡ Daniela Marasco,x
Paolo Botti,{ Laszlo Farkas,‖ Steven X. Cho,* Jarod A. Zepp,# Tania Azam,#
Hannah Dinkel,# Brent E. Palmer,# William A. Boisvert,† Carlyne D. Cool,**
Laima Taraseviciene-Stewart,# Bas Heinhuis,†† Leo A. B. Joosten,†† Charles A. Dinarello,#,††
Norbert F. Voelkel,**,1 and Marcel F. Nold*,1
IL-32 is a multifaceted cytokine with a role in infections, autoimmune diseases, and cancer, and it exerts diverse functions, including
aggravation of inflammation and inhibition of virus propagation. We previously identified IL-32 as a critical regulator of endothelial
cell (EC) functions, and we now reveal that IL-32 also possesses angiogenic properties. The hyperproliferative ECs of human pul-
monary arterial hypertension and glioblastoma multiforme exhibited a markedly increased abundance of IL-32, and, significantly,
the cytokine colocalized with integrin aVb3. Vascular endothelial growth factor (VEGF) receptor blockade, which resulted in EC
hyperproliferation, increased IL-32 three-fold. Small interfering RNA–mediated silencing of IL-32 negated the 58% proliferation of
ECs that occurred within 24 h in scrambled-transfected controls. Reduction of IL-32 neither affected apoptosis (insignificant changes
in Bak-1, Bcl-2, Bcl-xL, lactate dehydrogenase, annexin V, and propidium iodide) nor VEGF or TGF-b levels, but siIL-32–transfected
adult and neonatal ECs produced up to 61% less NO, IL-8, and matrix metalloproteinase-9, and up to 3-fold more activin A and
endostatin. In coculture-based angiogenesis assays, IL-32g dose-dependently increased tube formation up to 3-fold; an aVb3 inhibitor
prevented this activity and reduced IL-32g–induced IL-8 by 85%. In matrigel plugs loaded with IL-32g, VEGF, or vehicle and
injected into live mice, we observed the anticipated VEGF-induced increase in neocapillarization (8-fold versus vehicle), but unex-
pectedly, IL-32g was equally angiogenic. A second signal such as IFN-g was required to render cells responsive to exogenous IL-32g;
importantly, this was confirmed using a completely synthetic preparation of IL-32g. In summary, we add angiogenic properties that
are mediated by integrin aVb3 but VEGF-independent to the portfolio of IL-32, implicating a role for this versatile cytokine in
pulmonary arterial hypertension and neoplastic diseases. The Journal of Immunology, 2014, 192: 589–602.
S
ince its designation as a cytokine by Kim and colleagues
in 2005 (1), considerable progress has been made with
elucidating the properties of the unusual cytokine IL-32.
Structurally, IL-32 does not share similarities with known cyto-
kine families (1). Seven isoforms, IL-32a–z (1, 2), and one ad-
ditional isoform (3) have been described and alternative splicing
appears to have biological relevance. For example, in endothelial
cells (ECs), an isoform switch from a/g to b/ε occurs upon
stimulation with IL-1b or thrombin (4), and a protective function
for this splicing event has been suggested (5). Moreover, an iso-
form switch from IL-32g to IL-32b in tissues from patients with
rheumatoid arthritis is associated with an attenuation of inflam-
mation (6). A receptor for IL-32 is currently unknown, although
ligand-affinity column assays have shown that IL-32 can bind to
neutrophil proteinase-3 (7), and that subsequent processing alters
the biological activity of IL-32a and IL-32g (8).
The earlier studies on IL-32 focused mainly on its proinflam-
matory properties, for example the induction of other cytokines and
chemokines such as IL-1b, IL-6, and TNF, as well as Th1 and Th17-
associated cytokines, in various cells via activation of the p38 MAPK,
NF-kB, and AP-1 signal transduction pathways (1, 9). IL-32 is
present in increased abundance in a variety of diseases, including
chronic obstructive pulmonary disease (10), inflammatory bowel
disease and psoriasis (11), allergic rhinitis (12), and myasthenia
gravis (13), and its levels are directly related to disease severity in
rheumatoid arthritis (14, 15).
We and others have shown that IL-32 possesses antiviral
properties. For instance, silencing of IL-32 by small interfering (si)
RNA (siIL-32) resulted in increased production of HIV-1 (9) as
well as higher viral loads of vesicular stomatitis virus and HSV-2
(16). In each of these models, the abundance of IFNs was de-
pendent on the levels of IL-32, but the antiviral activity of IL-32
was only in part via type I IFNs. IL-32 has also been implicated in
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the immune response to influenza A (17), hepatitis B (18) and C
(19), papillomavirus (20), and the Venezuelan equine encephalitis
virus (21).
With regard to neoplastic diseases, IL-32 has been demonstrated
to modulate apoptosis in myelodysplastic syndromes and chronic
myeloid leukemia (22). IL-32 also exhibited antiapoptotic prop-
erties in pancreatic cancer cells (23) and was associated with a more
malignant phenotype in tumors of the lung (24). Conversely, IL-
32g overexpression by transgene or cell transfer inhibited the
growth of melanomas and colon tumors (25).
In ECs of various origin, IL-32 is a crucial mediator of proin-
flammatory stimuli such as IL-1b, thrombin, LPS, and platelets. We
found that the abundance of IL-32 was increased by treatment with
these triggers of EC inflammation, and silencing by siIL-32 resulted
in decreased production of proinflammatory IL-1a, IL-6, IL-8, and
ICAM-1, as well as increased expression of thrombomodulin/
CD141 (4). Furthermore, IL-32 has been shown to mediate giant
cell arteritis (26), to interact with integrins (27), and to play an
important role at multiple levels in atherosclerosis (5).
A dysregulation of the functions of ECs plays a major role in
pulmonary arterial hypertension (PAH). Several forms of PAH have
been classified, but many of them are characterized by complex
pulmonary vascular lesions. These lesions are multicellular and
demonstrate hyperproliferative ECs that grow in an uncontrolled
fashion to the point of obliteration of the vascular lumen (28).
Mechanisms likely involved in this pulmonary microvessel dis-
ease have recently been reviewed (29, 30). Importantly, the pro-
liferating ECs are apoptosis-resistant and form multiple lumina,
often with the appearance of glomeruloid structures or structures
that are reminiscent of the vascular coils observed in the tumors of
glioblastoma multiforme (GBM), a tumor that originates from EC
precursors (31). Increasingly a role for inflammatory cytokines
and immune cells in PAH is being recognized (32, 33); for ex-
ample, IL-1 and IL-6 plasma levels are increased in patients with
severe PAH (32). Although a consensus is building that inflam-
mation and immune mechanisms play a role in the pathobiology
of severe forms of PAH, little is known as to whether inflammation
causes the formation of the vascular lesions or how inflammatory
cells and immune cells contribute to the angio-obliteration (an-
giogenesis) of these remodeled lung vessels (34).
Because IL-32 acts as an important regulator of EC biology (4),
and because the prototypical angiogenic mediator vascular en-
dothelial growth factor (VEGF) is highly expressed in plexiform
vascular lung lesions (35), as well as in psoriatic angioprolifer-
ative skin lesions (36), we asked whether IL-32 could also func-
tion as an angiogenic factor.
Materials and Methods
Reagents
HUVECs media and additives were from Lonza (Walkersville, MD) or
from PromoCell (Heidelberg, Germany; ECGM MV, used in the coculture
experiments). Iscove’s DMEM, RPMI 1640, and M199 were obtained
from Life Technologies/Invitrogen (Carlsbad, CA). Human skin fibroblasts
(HSFs) and their medium (FGM2) were from PromoCell. PBS, FCS,
and penicillin/streptomycin were purchased from Cellgro (Herndon, VA).
Pooled human serum and Accutase were acquired from MP Biomedicals
(Solon, OH). LPS (O55:B5) was from Sigma-Aldrich (St. Louis, MO). The
Nucleofector II electroporation device and reagents as well as primocin
were from Amaxa (Cologne, Germany). siIL-32 was purchased from
Thermo Fisher Scientific (Lafayette, CO) and comprised four ON-
TARGETplus duplexes (I–IV) with the antisense sequences I, 59-UAA
UAA GCC GCC ACU GUC UUU-39; II, 59-CCG UAA UCC AUC UCU
UUC UUU-39; III, 59-UCA UCA GAG AGG ACC UUC GUU-39; and IV,
59-CAA GUA GAG GAG UGA GCU CUU-39. One sequence comprised
a quarter of the total siRNA concentration; that is, 25 nM of each se-
quence was pooled for a total siRNA concentration of 100 nM used in the
transfections. Scrambled siRNA (silencer negative control no. 1) was
purchased from Ambion (Austin, TX). Recombinant human IL-32g and
IL-1b and recombinant murine VEGF were from R&D Systems (Min-
neapolis, MN). As per the manufacturer, the endotoxin level in recom-
binant human IL-32g was ,1 endotoxin unit per microgram by the
Limulus amebocyte lysate method. All other recombinant cytokines were
bought from PeproTech (Rocky Hill, NJ). We generated the affinity-purified
anti-human IL-32 Ab and have used it previously (1, 9). FITC-labeled
Sambucus nigra lectin was from Vector Laboratories (Burlingame, CA).
The aVb3 inhibitor cyclo(Arg-Gly-Asp-D-Phe-Val) was obtained from Enzo
Life Sciences (Farmingdale, NY).
Generation of synthetic IL-32g
The chemical synthesis of IL-32g (103 residues) was performed following
a four-fragment strategy of native chemical ligation. Fragments used to
assemble the protein were 1) the N-terminal fragment, residues 1–35-Ca-
COS-R (F1); 2) the intermediate fragment, residues 36–56-Ca-COS-R
with an N-terminal Cys introduced as thiazolidine (F2a); 3) another in-
termediate fragment, residues 57–59-Ca-COS-R with an N-terminal Cys
introduced as thiazolidine (F2b); and 4) the C-terminal fragment, residues
60–103 (F3). F1, F2a, and F2b were assembled by the solid phase method
on a b-mercapto-propionic acid-glycine resin to generate C-terminal
thioesters with R indicating b-mercapto-propionic acid-glycine, follow-
ing Boc protocols with in situ neutralization and using related chemicals
(37). F3 was assembled by standard Fmoc chemistry on a Wang resin to
afford a C-terminal–free polypeptide. After cleavage, polypeptides were
purified to homogeneity by reversed phase HPLC and characterized by
liquid chromatography/mass spectrometry to assess purity and identity.
Native chemical ligation and thiazolidine opening reactions were per-
formed as reported elsewhere (37). The intermediate ligated polypeptides
IL-32 (57–103), IL-32 (36–103), and the final full-length 103 residue
products were also purified by reversed phase HPLC and characterized by
liquid chromatography/mass spectrometry to assess purity and identity: F1,
expected Mr of 4,011.6 kDa, found 4,011.4 (purity 90%); F2a, expected Mr
of 2,760.4 kDa, found 2,760.0 (purity 95%); F2b, expected Mr of 560.1
kDa, found 560.0 (purity 97%); F3, expected Mr of 5,042.5, found 5,043.0
(purity 95%); full-length IL-32g, expected Mr of 11,570.4 kDa, found
11,570.3 (purity .95%). The single-letter code sequence of the full-length
IL-32g is as follows, with the ligation sites in bold and underlined:
MCFPKVLSDD MKKLKARMVM LLPTSAQGLG AWVSACDTKD
TVGHPGPWRD KDPALWCQLC LSSQHQAIER FYDKMQNAES
GRGQVMSSLA ELEDDFKEGY LET.
Cell culture
HUVECs were isolated from human umbilical cords after informed consent
was obtained from the parents. All experiments were approved by the
Colorado Multiple Institutional Review Board. Cords were cleaned by
several high-volume rinses with HBSS. Thereafter, one end of the cord was
clamped and a catheter was inserted from the open end, through which the
umbilical vein was filled with 0.3% trypsin (Life Technologies). The
catheter was removed and the open end was clamped before the cord was
incubated for 30 min at 37˚C. Thereafter, the cord was massaged, the clamp
was removed, and the cord was squeezed lengthwise to force the content
into a collection tube. Two washes with HBSS were used to detach residual
cells from the vein. The collection tube was centrifuged at 300 3 g for 10
min, the pellet was resuspended in HUVEC growth medium (39% Iscove’s
DMEM, 38.6% RPMI 1640, 20% FCS, 0.4% endothelial mitogen [Bio-
medical Technologies], 17.6 U/ml heparin, 1% penicillin/streptomycin)
and transferred into cell culture flasks coated with 1% gelatin. For stim-
ulation, the medium was changed to endothelial cell stimulation medium
comprising M199 (Life Technologies) with 2% FCS, 10 ng/ml human
acidic fibroblast growth factor (PeproTech), 1% penicillin/streptomycin,
and 17.6 U/ml heparin.
Aortic macrovascular ECs as well as coronary and pulmonary micro-
vascular ECs were obtained from Lonza. Coronary and pulmonary ECs
were cultured in EGM-2-MV (Lonza) with a final concentration of 5% FCS.
Aortic ECs were grown in EGM-2 with a final concentration of 2% FCS.
PBMCs were isolated and cultured as described previously (38).
For the coculture experiments, HSFs were cultivated in a 48-well plate
(5 3 104 cells/well) and grown to confluence for 3 d in FGM2 plus
Supplement Mix (PromoCell). At day 3, HUVECs (5 3 104 cells/well)
were carefully added to the confluent HSFs. After 4 h of incubation,
HUVECs were attached and the incubation media were exchanged with
a 1:1 mixture of ECGM MV and FGM2 (plus the respective supplement
mix) with or without IL-32 (10, 25, 100 ng/ml) and with or without cyclo
(Arg-Gly-Asp-D-Phe-Val) (10 mM). Treatment with recombinant human
VEGF-165 (40 ng/ml) was used as internal assay control. The cells were
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cocultured for 7 d with two media changes at 37˚C and 5% CO2. Both
HUVECs and HSFs were used in passages two through eight and passaged
using a DetachKit (PromoCell).
Transfections
HUVECs were detached, counted, centrifuged at 200 3 g for 12 min, and
subjected to electroporation using the Amaxa HUVEC Nucleofector kit
and program U001. One cuvette contained 0.8 3 106 cells in 100 ml
Nucleofector solution and 25–333 nM either siIL-32 or scrambled. Im-
mediately after electroporation, the cells were incubated in 300 ml pre-
warmed M199 for 5 min. Thereafter, 0.2 3 106 cells were transferred into
gelatinized six-well plates (Greiner Bio-One, Ocala, FL) to a final volume
of 1 ml growth medium and allowed to recover overnight. On the next day,
the medium was replaced with stimulation medium and the cells were
stimulated.
Immunohistochemistry
Briefly, after paraffin-embedded sections were cut at 5-mm sections, the
slides were deparaffinized and transferred through progressive ethanol
gradients for rehydration. High-temperature Ag retrieval was performed in
10 mM/l citrate buffer (pH 6.0) for 30 min. Endogenous peroxidase was
quenched with 3% hydrogen peroxide for 15 min twice. All immunostains
were performed using the Dako Universal LSAB+ kit/HRP-based visual-
ization kit. Primary Ab incubation was performed at 1:1500 dilution for 30
min. Chromagen development was performed with 3,39-diaminobenzidine
and counterstained with hematoxylin. Normal blocking serum without
primary Ab was used for the negative control.
Immunofluorescence and confocal microscopy
Paraffin-embedded human lung tissue, obtained from patients with idio-
pathic PAH, and control tissue from patients without pulmonary vascular
disease were used for double immunofluorescence. First, slides were
steamed for 20 min in 0.01 M citrate buffer (pH 6.0) and blocked with 1%
normal swine serum for 15 min. Primary Ab no. 1, IL-32 (1:50; Abcam,
Cambridge, MA), was applied overnight at 4˚C in 1% normal swine serum.
Secondary Ab no. 1, anti-rabbit Alexa Fluor 594 (1:100; Invitrogen,
Carlsbad, CA), was incubated for 4 h at room temperature in PBS. Sections
were incubated with primary Ab no. 2, anti-mouse von Willebrand factor
(vWF) (1:20; LifeSpan Biosciences, Seattle, WA), overnight at 4˚C in
PBS, then secondary Ab no. 2, anti-mouse Alexa Fluor 488 (1:100; Invi-
trogen), was applied for 4 h at room temperature in PBS. Slides were
counterstained with DAPI at 1:20,000 and mounted with SlowFade anti-
fade (both from Invitrogen). Negative controls with unspecific IgG were
run in parallel. Optical sections were acquired by laser- scanning confocal
microscopy with a Leica TCS-SP2 confocal microscope and images were
analyzed and arranged with ImageJ. Microscopy was performed at the
Virginia Commonwealth University Department of Anatomy and Neuro-
biology Microscopy Facility.
Electrochemiluminescence assays and ELISAs
Human IL-6 and IL-32 were measured using specific Ab pairs and an Origen
analyzer (Wellstat Diagnostics, Gaithersburg, MD) as described previously
(9); Ab pairs for all cytokines were obtained from R&D Systems. The IL-6
ELISA was obtained from Elisakit.com (Scoresby, VIC, Australia).
TGF-b1 was determined by ELISA (R&D Systems) according to the
manufacturer’s instructions. Recombinant cytokines for electrochem-
iluminescence or ELISA standards were obtained from R&D Systems
or PeproTech.
Real-time PCR analysis
RNA was extracted from HUVECs using the RNA Mini kit (Bioline,
Alexandria, NSW, Australia) and then quantified with the NanoDrop (ND-
1000) spectrophotometer (Thermo Scientific, Wilmington, DE). RNA was
reversely transcribed using a high-capacity cDNA reverse transcription kit
(Applied Biosystems, Melbourne, VIC, Australia) as per the manufacturer’s
instructions. SYBR Green quantitative RT-PCRs were run on the Applied
Biosystems 7900HT Fast RT-PCR system. Oligonucleotide primers
(forward/reverse) were as follows: 18S, 59-CCC CTC GAT GCT CTT
AGC TG-39 and 59-CTT TCG CTC TGG TCC GTC TT-39; activin A, 59-
GTT TGC CGAGTC AGG AAC AG-39 and 59-CCC TTTAAG CCC ACT
TCC TC-39; angiogenin, 59-GCC GAG GAG CCT GTG TT-39 and 59-
GCG CTT GTT GCC ATG AAT-39; angiopoietin 2, 59-AGC TAA GGA
CCC CAC TGT TG-39 and 59-TGA AGG GTTACC AAATCC CAC T-39;
Bak-1, 59-CCA CCA GCC TGT TTG AGA GT-39 and 59-AAA CTG GCC
CAA CAG AAC CA-39; Bcl-2, 59-CGC GAC TCC TGATTC ATT GG-39
and 59-CAG TCT ACT TCC TCT GTG ATG TTG T-39; Bcl-xL, 59-ACT
CTT CCG GGA TGG GGT AA-39 and 59-ACA AAA GTA TCC CAG
CCG CC-39; endoglin, 59-GCC CCA CAA GTC TTG CAG AA-39 and 59-
GCT TGG ATG CCT GGA GAG TC-39; IL-8, 59-ACT CCA AAC CTT
TCC ACC CC-39 and 59-GCG GAA GAT GAC CTT CTC CT-39; and
u-plasminogen activator, 59-GTC GTG AGC GAC TCC AAA GG-39 and
59-GAC TTA TCT ATT TCA CAG TGC TGC C-39. No template controls
were included in parallel for each gene master mix. The cycling conditions
were as follows: denaturation at 95˚C for 10 min, followed by 40 cycles of
denaturation at 95˚C for 15 s, annealing and elongation at 60˚C for 1 min.
These cycles were followed by a melt-curve analysis, 95˚C for 15 s, 60˚C
for 15 s, followed by 95˚C for 15 s. Relative expression quantification was
calculated using Pffafl’s method. All fold changes in gene expression were
normalized to 18S mRNA.
MTS assay
The CellTiter cell proliferation assay was purchased from Promega
(Madison, WI) and executed according to the manufacturer’s instructions.
Briefly, cells were transfected and 2000 cells in 100 ml stimulation medium
were seeded into a 96-well plate. Cells were grown for 3 d, then 20 ml
MTS reagent was added to each well, followed by a further 2 h incubation.
Then the absorbance at 490 nm was recorded in a plate reader. The
quantity of the formazan product as measured by the absorbance is pro-
portional to the number of living cells in the cultures.
Determination of nitrate/nitrite
Supernatants from EC cultures were collected and assayed for total
nitrate/nitrite concentration using a kit provided by Cayman Chemical
(Ann Arbor, MI).
In vitro angiogenesis model
On day 7 of coculture, cells were washed with PBS, fixed with 2% para-
formaldehyde (pH 7.4) for 10 min at room temperature, treated with 0.1%
Triton X-100, and blocked with 2% BSA in PBS. Thereafter, the coculture
was incubated with Sambucus nigra lectin-FITC (20 mg/ml) for 1 h at room
termperature in the dark. Cell nuclei were labeled using DAPI. Cells were
washed thoroughly, covered with PBS, and examined microscopically on
an Axiovert (Carl Zeiss, Jena, Germany). Five fields of view per condition
were randomly chosen and photographed. The number of visible branches
was counted using ImageJ.
Matrigel-related procedures in vivo
All animal experiments were approved by the Colorado Multiple Institu-
tional Review Board. Vehicle (NaCl 0.9%), VEGF, or rIL-32g (both R&D
Systems) was mixed with growth factor–reduced high-concentration
matrigel (BD Biosciences, San Diego, CA) at 4˚C. Thereafter, each
mouse (male ICR mice) received an s.c. injection with two 200 ml aliquots
of matrigel with nonidentical contents on the right and left sides of the
abdominal wall. The mice were allowed free access to food and water for
14 d, followed by harvest of the plugs as described below.
Histopathological analysis and scoring of matrigel plugs
This analysis was performed by Premier Laboratory (Boulder, CO). Each
of the scientists at Premier Laboratory was blinded to the content of the
matrigel plugs. Matrigel plugs and the surrounding tissue, skin, and muscle
were removed at necropsy and placed into 10% neutral buffered formalin.
The plugs were bisected, processed, and embedded in paraffin. Multiple
sections were cut, one was stained with H&E, and another was immuno-
histochemically stained for CD31 wherein slides were dewaxed in xylene
and hydrated to water through a series of alcohol gradients. Prior to
staining, the tissue sections were pretreated with a TRIS/EDTA (pH 9.0)
target retrieval solution (Dako, K8004) and incubated for 2 h at 70˚C. A
3.0% hydrogen peroxide solution was used for 5 min at room temperature
to quench any endogenous peroxidase activity within the tissue. Serum-
free protein block (Dako, X0909) was used to neutralize any charged
molecules that may cause nonspecific Ab binding. The rat anti-mouse
CD31/PECAM-1 Ab (Dianova, Hamburg, Germany) was applied to the
tissue sections at a working concentration of 5.0 mg/ml (1:40) from the
stock solution for 60 min at room temperature. The primary Ab was then
conjugated with a biotinylated rabbit anti-rat Ig (Dako, E0468) at a con-
centration of 2.125 mg/ml (1:400) for 30 min at room temperature. The
biotinylated secondary Ab was then amplified with a goat anti-rabbit–la-
beled polymer (Dako, K4003) for 30 min at room temperature. Thereafter,
staining was developed with liquid diaminobenzidine for 5 min at room
temperature (Dako, K3468). Counterstaining was developed with auto-
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mated hematoxylin (Dako, S3301) for 10 min. The negative control so-
lution for this immunohistochemical stain was an unconjugated rat IgG2a
isotype Ab (AbD Serotec, MCA1124) that was used at the same working
concentration as the primary Ab.
The H&E-stained slides were reviewed by a board-certified veterinary
pathologist. The evaluation included the degree of fibrosis in the subcutis
adjacent to each implant as well as the inflammatory response in the
subcutis and the overall cellularity within each implant. For scoring the
metrics identified in the figures, the most advanced changes within an
implant were used for scoring. Neocapillaries were defined by the presence
of oval-circular structures containing RBCs and associated with concen-
trically arranged mesenchymal nuclei (fibroblasts and endothelial cells). A
subjective, semiquantitative scoring system was used: 0, no significant
change; 1, minimal change; 2, mild change; 3, moderate change; and 4,
marked change.
The CD31-stained slides were scanned on an Aperio ScanScope XT.
Then the area of matrigel implant was traced and analyzed via Aperio’s
microvessel algorithm that calculated the number of vessels and micro-
vessel density along with other parameters.
Statistical analysis
Datasets (raw data) were first tested for normality by the Kolmogorov–
Smirnov method and equal variance (p value to reject 0.05) using the
SigmaStat software (Systat Software, San Jose, CA). Thereafter, these data
were analyzed by the appropriate statistical test, including Student t test,
one-way ANOVA, and one-way ANOVA on ranks.
Results
IL-32 in tissue sections from patients with PAH and in an
in vitro model of pulmonary angioproliferation induced by
VEGF receptor blockade
We reported that IL-32 is important in EC biology (4). Therefore,
a next reasonable step was to investigate the role of this cytokine
in diseases that involve ECs. We stained tissue sections from
patients with PAH using two different Abs against IL-32 (Fig. 1).
In a normal human lung arteriole, IL-32 was detected in the
vascular smooth muscle cells of the medial layer (shown in red
in Fig. 1A), but not in the endothelial monolayer, as highlighted
by vWF staining in green. On the other hand, the ECs in lung
specimens from patients with idiopathic PAH did express IL-32.
Fig. 1B shows a patent arteriole, with the arrowheads in the insets
pointing to the IL-32+ ECs. When we examined the characteristic
plexiform lesions, which are diagnostic for idiopathic PAH (28,
31), we found a yet higher abundance of IL-32 within the
hyperproliferative ECs that grow to obstruct the blood vessels. In
the specimen in Fig. 1C, which was obtained from the same pa-
tient displayed in Fig. 1B, an arteriolar vessel is almost completely
obliterated by the IL-32–expressing, hyperproliferative ECs. Some
of these ECs, particularly in the center of the lesion, have very
large nuclei (stained by DAPI in blue) and are activated, pheno-
typically switched cells that have lost the vWF marker. Fig. 1D
and the insets show more detail at a higher magnification and the
colocalization of vWF and IL-32 (arrows). Fig. 1E–H demonstrate
a similar pattern of IL-32 expression when we used classical
immunohistochemistry. The red arrowheads point to the expres-
sion of IL-32 in the proliferating ECs. We also found IL-32 in the
bronchial epithelium (golden arrows), which was expected based
on an earlier study (10). For negative control, we performed the
staining in the absence of the primary Abs and observed no
staining on any specimen (data not shown).
We previously reported that blockade of the VEGF receptor by
the small molecule inhibitor semaxanib (Su5416) initially causes
apoptosis. However, ECs surviving this initial phase become
hyperproliferative and grow in an uncontrolled fashion, which can
result in obstruction of the lumen of artificial capillaries (39),
resembling the pathology of PAH (Fig. 1A–H). Hence, treatment
of ECs with semaxanib can be regarded as a model of this disease,
which we employed to confirm the immunohistochemistry re-
sults. As depicted in Fig. 1I, IL-32 protein levels increased up to
3.4-fold as HUVECs underwent the transformation into the
hyperproliferative state. In three of four experiments, IL-32 ex-
pression peaked on day 3. However, in the ECs from the fourth
cord, which, unlike the other HUVECs, contained considerably
less IL-32 in semaxanib-treated cells than did vehicle-treated
controls 24 h after the initial stimulation, the maximal increase
in IL-32 protein expression occurred on day 7 (brown line and
points in Fig. 1I).
IL-32 in GBM
Based on the findings in the lung, we hypothesized that expression
of IL-32 may be associated with augmented proliferation of ECs.
To examine this hypothesis, we stained tissue sections from GBM,
which is a malignant brain tumor where EC growth (angiogenesis)
is of critical importance for tumor growth. Again, we observed only
occasional staining of IL-32 in unaffected areas of the brain. The
tumor cells, however, showed massive expression of IL-32 protein
(red arrows in Fig. 2). Negative control experiments were per-
formed as described in the previous section and did not exhibit any
color changes (data not shown).
siIL-32 reduces the proliferation of ECs, but changes in IL-32
protein abundance do not affect EC apoptosis
Nearly all of the experiments in this study in which siIL-32 was
used were performed together with those we have previously
published (4). In fact, the same supernatants and lysates were
used in most cases; therefore, Fig. 3A and 3B, which show the
concentration-dependent knockdown of IL-32 protein by siIL-32
compared with scrambled siRNAwithout (Fig. 3A) or with IL-1b
stimulation (Fig. 3B), are recycled from our earlier studies (4).
Because the abundance of IL-32 was increased in hyper-
proliferative ECs, we reasoned that silencing of this cytokine
should result in a reduction of proliferation of HUVECs. When we
knocked down IL-32 with siRNA, we observed that a reduction of
IL-32 protein had moderate effects on cell numbers in vehicle-
treated HUVECs (left pair of bars in Fig. 3C). However, upon
stimulation with IL-1b, a reduction of IL-32 by 76% resulted in
a decrease in proliferation from +58% in scrambled siRNA-
transfected HUVECs to 215% (right pair of bars in Fig. 3C).
To gather additional evidence, we used an MTS assay in which the
production of dye is proportional to the number of live cells. As
shown in Fig. 3D, the proliferation of IL-1b–stimulated HUVECs
was reduced by .50% upon silencing of IL-32 compared with
scrambled siRNA-transfected cells. Similar to Fig. 3C, the effect
was less pronounced in unstimulated HUVECs.
Next, we performed experiments to answer the important
question of whether the reduction in cell numbers conferred by
siIL-32 was due to an increase in apoptosis or truly due to a de-
crease in proliferation. Using flow cytometric quantification of
annexin V to detect the presence of ongoing apoptosis and pro-
pidium iodide (PI) to identify cells during late apoptosis and ne-
crosis, we found that siIL-32 conferred a moderate (statistically not
significant) increase of annexin V and PI in HUVECs (up to 1.4-
fold 6 11% more annexin V and up to 1.2-fold 6 9% more PI
compared with scrambled siRNA; n = 6, p . 0.2). In pulmonary
microvascular ECs, this trend was slightly more pronounced but
still not significant with 1.7-fold 6 0.32% more annexin V and
1.6-fold 6 41% more PI with siIL-32 (n = 8, p . 0.1). Further-
more, we performed measurements of LDH in the culture super-
natants, which also showed that siIL-32 did not result in an
increase in cell death (no difference between scrambled and
siRNA to IL-32). To be as certain as possible about this crucial
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aspect, we next treated HUVECs with exogenous IL-32g in the
presence or absence of IFN-g pretreatment (described below) and
measured the mRNA abundance of bak1, bcl2, and bclxl by real-
time PCR. None of the three mediators of apoptosis exhibited
FIGURE 1. IL-32 in PAH. (A–D) Triple-label immunofluorescence images of human lung vessels. IL-32 is stained in red, vWF in green, and nuclei in
blue (DAPI). Scale bar, 50 mm. (A) Staining of a normal pulmonary arteriole (arrow) from a patient not suffering from PAH. Image is representative of three
similar results. (B–D) Specimen from one out of a total of three similar patients with idiopathic PAH. (B) An affected but not obliterated arteriole with
activated ECs is depicted. Dotted lines indicate areas that are enlarged in insets on right. The arrowheads point to EC expression of IL-32. (C, D) A
plexiform lesion is shown, in which the lumen of the blood vessel is obliterated by hyperproliferative ECs. Dotted line indicates area that is enlarged in (D),
and yet more detail is provided in insets on right. The arrowheads point to the hyperproliferative ECs that stain positive for IL-32 and vWF. (E–H) Classical
immunohistochemistry of IL-32 in lung specimen of PAH patients. After incubation with the primary Ab to IL-32, slides were stained with dia-
minobenzidine and hematoxylin. Diseased, hyperproliferative pulmonary blood vessels with a markedly thickened endothelium are shown in overview in
(E) (original magnification3100) and in detail in (F)–(H) (original magnification3200). The innermost endothelial layer contains a considerable amount of
IL-32 protein (red arrows). Staining is also seen in alveolar epithelial cells (golden arrows). Images are representative of three patients. (I) HUVECs were
plated and grown for 24 h. Thereafter, the medium was changed to stimulation medium (2% FCS, see Materials and Methods) and either semaxanib (10
mM) or vehicle was added. Cells were harvested after the indicated periods of time and lysates were assayed for IL-32 protein and total protein. IL-32
abundance was normalized to total protein, fold increases in normalized IL-32 abundance were calculated (IL-32 in semaxanib-treated cells divided by IL-
32 in vehicle-treated cells), and IL-32 abundance in vehicle-treated cells was set at 1. Each line indicates fold change in semaxanib-treated cells over
vehicle-treated cells in one time course experiment (n = 4). *p , 0.05 for semaxanib versus vehicle.
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a significant change in mRNA abundance in IL-32g–stimulated
cells compared with controls (bak1 up to 19 6 7% increased, bcl2
up to 19 6 6% decreased, and bclxl up to 17 6 7% increased; n =
4, p . 0.3). These findings are highly unlikely to be an artifact, as
the data on IL-8 (which show a pronounced regulation; see Fig.
7G) were obtained from the same samples. Taken together, these
data show that the angiogenic effect of IL-32 is not due to
a change in apoptotic programming.
siIL-32 in ECs: TGF-b1, NO, and VEGF
We further explored the actions of IL-32 using ECs in which IL-32
was silenced by siRNA and measured the concentrations of TGF-
b1 and NO, two mediators known to play a role in PAH (40). As
demonstrated in Fig. 3E, we found that the concentration of NO
decreased by 61% from 13 to 5 pg/mg total protein in unstimu-
lated HUVECs in which IL-32 was reduced. In contrast, the
abundance of TGF-b1 did not change significantly with siIL-32
(data not shown). Unexpectedly, this was the case for VEGF
as well; in fact, the abundance of VEGF was slightly though
nonsignificantly higher in ECs transfected with siIL-32 (vehicle,
400 6 72 versus 508 6 64 pg/mg total protein in scrambled-
transfected versus siIL-32–transfected cultures, respectively, p =
0.09; IL-1b–stimulated HUVECs, 810 6 87 versus 1082 6 195
pg/mg total protein in scr versus siIL-32, p = 0.54; n = 9).
Pretreatment with IFN-g sensitizes ECs to exogenous IL-32g
Next, we attempted to confirm the findings obtained by silencing
IL-32 by incubating the HUVECs with exogenous rIL-32g. We
expected to observe inverse effects, but instead exogenous IL-
32g did not affect any of the parameters described previously
at concentrations between 1 and 500 ng/ml. However, when
HUVECs were pretreated with IFN-g for 24 h, stimulation with
exogenous IL-32g resulted in the expected findings; in IFN-g–
pretreated cells, the concentrations of IL-32g needed to elicit IL-
6 production were as low as 10 ng/ml. As demonstrated in Fig.
4A, IFN-g alone conferred a moderate, up to 39%, reduction in
the production of IL-6. Treatment with IL-32g alone had only
marginal effects, but together with IFN-g, the abundance of IL-6
increased up to 2.3-fold over control and 3.8-fold over IFN-g
alone. This increase was dependent on the concentration of both
IL-32g and IFN-g.
Interestingly, the sensitization effect was specific to IFN-g. We
also pretreated the HUVEC cultures with IL-1b (1 and 10 ng/
ml), LPS (10 and 100 ng/ml), muramyl dipeptide (0.2 and 1 mg/
ml), thrombin (0.1 and 0.5 U/ml), or VEGF at 1 and 10 ng/ml,
none of which increased the responsiveness of the cells to ex-
ogenous IL-32g.
To further characterize this unexpected effect, we tested whether
IFN-g pretreatment increased the response to a different prepa-
ration of exogenous IL-32g in a different cell type. We generated
a completely synthetic IL-32g peptide and added this protein to
PBMC cultures that had been pretreated with IFN-g or vehicle.
Fig. 4B and 4C show that IFN-g indeed sensitized PBMCs. The
abundance of IL-6 was up to 8-fold higher and that of TNF was up
to 24-fold increased compared with exogenous synthetic IL-32g
alone, whereas the effects of IFN-g alone were negligible.
In vivo angiogenesis assays (matrigel)
To obtain in vivo evidence for the angiogenic properties of IL-32,
we employed the matrigel method (41, 42). Growth factor–reduced
matrigel was loaded with two different concentrations of rIL-32g
(25 and 100 ng/ml), VEGF (25 ng/ml) for positive control, or
vehicle for negative control and injected s.c. The plugs and the
surrounding tissue were harvested 14 d later. After cutting, the
sections were stained for the endothelial marker CD31 and then
analyzed for the formation of capillaries using both a semiquan-
titative scoring system, in which 0 represented no change, 4 stood
for maximum change, and 1, 2, and 3 for intermediate levels of
change, as well as an automated algorithm that was based on
CD31+ cells. Functionality of the new vessels was ascertained by
confirming the presence of RBCs within them. Additionally, we
assessed the infiltration of the plugs by other cells, which were
identified by morphology and subjected to the semiquantitative
scoring system described above.
Most importantly, we observed that, compared with vehicle, 100
ng/ml IL-32g in the matrigel plug induced a marked angiogenic
response; in fact, this response was stronger than that of 25 ng/ml
VEGF. Fig. 5 shows slides representative of this effect. Whereas in
the VEGF-loaded plugs (a representative one shown in Fig. 5B)
the mean score for the formation of new capillaries was 1.65, that
score was 1.70 in the plugs loaded with 100 ng/ml IL-32g (ex-
FIGURE 2. IL-32 in GBM. Immunohistochemistry with an Ab against
IL-32 in sections of brains affected by GBM was performed and is
depicted at an original magnification of 3100 (A, B) or 3200 (C). Strong
staining for IL-32 protein is observed in areas affected by the tumor (red
arrows). Images are representative for those obtained from a total of three
GBM patients.
594 IL-32 PROMOTES ANGIOGENESIS
 at U
niv di N
apoli/Federico II on February 2, 2016
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
emplary plug at 310 and 320 magnification; Fig. 5E and 5F,
respectively). Furthermore, 25 ng/ml IL-32g still resulted in
a mean score of 0.78 (Fig. 5C, 5D), with the vehicle-loaded plugs
scoring 0.20 (Fig. 5A; a quantitative summary is depicted in Fig.
6A). These results obtained by semiquantitative scoring were
confirmed by subjecting the same slides to automated counting
using the capillary algorithm of the Aperio software. As shown in
Fig. 6B, this method produced similar increases, namely 3.5-, 7-,
and 6-fold for 25 and 100 ng/ml IL-32g and VEGF, respectively,
over control. Owing to the greater variation of the data, only the
neocapillarization induced by 100 ng/ml IL-32g was statistically
significant when the computer-based analysis was used. The mean
vessel area of the neocapillaries induced by IL-32g was moder-
ately larger than in control and VEGF plugs (49 mm2 in control
and VEGF plugs versus 55 and 72 mm2 in 25 and 100 ng/ml IL-
32g, respectively; Fig. 6C).
To ascertain specificity, we also performed the matrigel assay
with plugs loaded with 10 ng/ml LPS. Angiogenesis in these plugs
was equal to that in vehicle controls.
With regard to other observations, the overall cellularity within the
implants wasmainly composed of inflammatory cells, lipid-containing
cells, neocapillaries, and fibroblasts. In the tissue adjacent to the
matrigel plugs, the scores for the presence of inflammatory cells as
well as fibroblasts showed only minor differences. In the implants,
however, IL-32g induced an increase in lipoidosis at both concen-
trations (Fig. 6D), whereas this effect was mild and not significant
with VEGF. As shown in Fig. 6E, a degree of infiltration with in-
flammatory cells was observed in each of the slides, and there was no
difference between the treatment groups. The inflammatory response
was mixed, with both polymorphonuclear cells (PMNs) as well
as lymphocytes present. Where the inflammation was more advanced,
and extended farther into surrounding tissues, PMNs predominated.
When the inflammatory response was minimal or mild, a scattering of
PMNs and/or lymphocytes/macrophages was apparent within or as-
sociated with the subcutis and fibrous connective tissue layer.
The integrin aVb3 colocalizes with IL-32 in PAH and mediates
its angiogenic activities
We recently reported the interaction of IL-32g with the integrin
aVb3 (27). Therefore, we investigated whether this interaction
occurred in human PAH. Indeed, confocal microscopy experi-
ments demonstrated that IL-32 colocalized with aVb3 in the
plexiform lesions of PAH (Fig. 7B–F), but not in the endothelium
of normal pulmonary blood vessels (Fig. 7A), in which the ex-
pression of aVb3 was low.
To further explore the mechanisms by which IL-32 exerted its
angiogenic properties, we first subjected samples from siIL-32 or
scrambled-transfected and vehicle- or IL-1b–stimulated HUVECs
to angiogenesis profiling analysis. Consistent with the proangio-
genic state conferred by IL-32, we found that the antiangiogenic
activin A, endostatin, and angiopoietin 2 were increased 3-, 2-,
and 2-fold when IL-32 was reduced, whereas the proangiogenic
IL-8, u-plasminogen activator, and matrix metalloproteinase
(MMP)-9 were up to 55% decreased. On the other hand, there was
FIGURE 3. Proliferation and NO abundance after silencing of IL-32 in HUVECs. (A and B) These panels are reprinted with permission from Nold-
Petry et al. (4), because the results in this figure were obtained from the same lysates and supernatants as those in figures 4 and 5 in Ref. 4. Transfection
of HUVECs with either the indicated concentrations of siIL-32 or scrambled siRNAwas followed by stimulation with 10 ng/ml IL-1b (B) or vehicle (A)
for 20 h. Means6 SEM of IL-32 abundance in cell lysates normalized to total protein (t.p.) is depicted; n = 10. (C) HUVECs were gently detached from
the plates and viable cells were counted by hand using the trypan blue exclusion method. The number of cells seeded after transfection was set as
baseline. Mean percentage change in siIL-32–transfected cells compared with scr-transfected cells 6 SEM is shown (n = 4). (D) After transfection with
the indicated concentration of siIL-32 or the same concentration of scrambled siRNA, cells were plated, IL-1b (10 ng/ml) or vehicle was added, and the
cultures were incubated for 3 d. Thereafter, MTS assays were performed. The graph shows means of percentage changes 6 SEM in the number of live
cells, comparing 25 or 100 nM siIL-32 to the appropriate concentration of scrambled siRNA, which is set at 100% (n = 6). (E) Supernatants from
HUVECs transfected with 100 nM siIL-32 or scrambled siRNA were collected after 48 h and assayed for total nitrate/nitrite concentration. Mean
concentration of total NO normalized to total protein (t.p.)6 SEM is depicted (n = 6). All statistical comparisons are as follows: *p, 0.05, **p, 0.01,
***p , 0.001 for siIL-32 versus scrambled siRNA.
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up to 3.5-fold more angiogenin and endoglin in siIL-32–trans-
fected HUVECs under unstimulated conditions, but no change
was detected after treatment with IL-1b. Next, we treated HUVEC
cultures with exogenous rIL-32g in the presence or absence of the
aVb3 inhibitor cyclo(Arg-Gly-Asp-D-Phe-Val) and of IFN-g
pretreatment and performed real-time PCR analysis. As shown in
Fig. 7G, exogenous IL-32g dose-dependently induced IL-8 but
only when the cells were pretreated with IFN-g (up to 2.5-fold
over IFN-g alone). Importantly, blockade of the integrin aVb3
reduced the IL-32g plus IFN-g–induced increase in IL-8 mRNA
by up to 85%. We also performed PCR analysis of the other
mediators of angiogenesis that exhibited a change on the profiler;
these experiments showed a reduction by IL-32g plus IFN-g and
a blockade of the effect by the aVb3 inhibitor for activin A, but
only small changes for the other mediators. This weaker effect of
exogenous IL-32 even with IFN-g pretreatment in comparison
with siIL-32 is consistent with our previous experience with this
cytokine (9, 16).
To demonstrate that aVb3 indeed contributes to the angiogenic
effects of IL-32, we next performed an angiogenesis assay in
which HUVECs or human aortic ECs (HAoECs) were cocultured
with human dermal fibroblasts (43). In this assay, exogenous rIL-
32g did not require IFN-g, but without a costimulus markedly
increased tube formation in a dose-dependent fashion (up to 3-
fold; Fig. 8). Consistent with the regulation of IL-8 described
above, the IL-32–induced angiogenesis was dependent on func-
tional aVb3, as cyclo(Arg-Gly-Asp-D-Phe-Val) potently reduced
the angiogenetic activity of IL-32g (by up to 72%; Fig. 8B, 8C). In
HAoECs, the angiogenetic activity of IL-32g at 100 ng/ml was
comparable to that of 40 ng/ml VEGF (3-fold versus 3.6-fold
increase in tube formation), thus resembling our findings in the
matrigel experiments. This effect was somewhat weaker, although
still significant, in the HUVECs (2-fold versus 3.5-fold increase in
tube formation).
Discussion
The major finding of our investigation is the discovery that IL-32
possesses angiogenic properties. Additionally, we revealed
that these properties, which are at least in part mediated by the
integrin aVb3, are relevant in vivo (exemplified by examination
of ECs in PAH and GBM), and are not mediated by VEGF.
Moreover, we demonstrate that pretreatment with IFN-g sen-
sitizes ECs of neonatal as well as adult pulmonary origin to
exogenous IL-32g, which without IFN-g is inactive when used
as a stimulant in these cells. This finding may be clinically
relevant, as there is some evidence that IFN-g may play a det-
rimental role in PAH (44, 45). In coculture of HUVECs or
HAoECs with HSF and in vivo in matrigel assays, IFN-g was
not required, and exogenous IL-32g effectively induced an-
giogenesis when added alone. However, the preparation of re-
combinant human IL-32g we used contained a small amount of
LPS (see later in the article). This small quantity of LPS, or
another factor present in these complex experimental systems,
may have substituted for IFN-g in providing a cofactor that
renders IL-32 functional. This concept is backed by similar
data obtained with a completely synthetic IL-32g preparation,
which also required a cofactor (IFN-g) to exert its biological
activity. One possible explanation is that IFN-g may induce
expression and/or transport to the cell surface of the yet un-
known receptor for IL-32. Because we moreover confirmed the
colocalization and functional relationship between IL-32 and
the integrin aVb3, and because integrins are known to be IFN-
g–inducible (46, 47), it is possible that aVb3 may act as a
receptor for IL-32 on ECs. In more general terms, these data
show that a second signal is necessary to render cells respon-
sive to exogenous IL-32.
FIGURE 4. IFN-g sensitizes cells to exogenous IL-32g. (A) After the
medium was changed from growth to stimulation medium, HUVECs were
treated with the indicated concentrations of IFN-g (ng/ml) or vehicle for
24 h. Thereafter, rIL-32g or vehicle was added at the concentrations in-
dicated (ng/ml). IL-6 was measured in the culture supernatants after an-
other 24 h. The graph shows means of fold changes in normalized IL-6
protein abundance comparing vehicle (control, set as 1) with stimulated
conditions 6 SEM (n = 7). *p , 0.05, **p , 0.01 for IFN-g alone versus
IL-32g plus IFN-g. (B and C) PBMCs were incubated with 10 ng/ml IFN-g
or vehicle for 24 h, followed by addition of synthetic (s)IL-32g at the
indicated final concentrations in ng/ml. Supernatants were harvested 24 h
later and assayed for IL-6 (B) and TNF (C). Absolute concentrations of
both cytokines 6 SEM are depicted (n = 4 healthy donors). Gray bar (far
left), medium alone; black bar (second from left), IFN-g alone; open bars,
sIL-32g alone; striped bars, sIL-32g plus IFN-g. *p, 0.05, **p, 0.01 for
sIL-32g alone versus sIL-32g plus IFN-g. n.d., Not detected.
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We have previously reported that the production of IL-32 protein
by ECs is enhanced by various stimuli, most notably by IL-1b,
which increases the abundance of IL-32 in EC lysates up to 15-
fold, even at low concentrations (4). In that report, we furthermore
demonstrated that IL-32 mediates the proinflammatory effects of
IL-1b in ECs, as silencing of IL-32 reduced the IL-1b–triggered
production of IL-1a, IL-6, IL-8, and ICAM-1 and simultaneously
increased the expression of thrombomodulin/CD141.
Each of these proteins has been implicated in the regulation of
angiogenesis directly or indirectly, but IL-1 and IL-8 are partic-
ularly well established as potent promoters of angiogenesis (for
examples, see Refs. 42, 48–51). Therefore, it was a logical next
step to explore whether IL-32 itself exerted any effects on the
proliferation of EC.
We localized IL-32 to the abnormal ECs that populate the so-
called plexiform lesions in the lungs from patients with idiopathic
PAH (34). These complex lung vascular abnormalities are charac-
terized by high expression of hypoxia-inducible factor-1a, VEGF,
and VEGF receptor 2 genes and proteins, thus presenting an angio-
genic signature (35). One pathogenetic concept is that EC injury and
apoptosis occur at sites of precapillary arterial bifurcations (28)
and that the remaining apoptosis-resistant ECs undergo a pheno-
FIGURE 5. IL-32g induces angiogenesis in vivo. Growth factor–reduced high concentration matrigel was mixed with vehicle (A), 25 ng/ml VEGF (B), or
rIL-32g at 25 ng/ml (C, D), or at 100 ng/ml (E, F); n = 10 plugs for each condition. Two 200 ml aliquots of matrigel with nonidentical contents were then
injected on the right and left sides of the abdominal wall of male ICR mice. The plugs were harvested 14 d later, followed by cutting and staining for CD31
(chromagens were diaminobenzidine and hematoxylin). The coworkers involved in the analysis of the matrigel experiments were blinded to the reagent
with which each individual plug was loaded. Blinding was lifted only after the completion of all aspects of the analysis. Representative plugs loaded with
vehicle [(A) original magnification 310], VEGF at 25 ng/ml [(B) original magnification 320], or IL-32g at 25 ng/ml [(C, D) original magnification 310
and 320, respectively], or 100 ng/ml [(E, F) original magnification 310 and 320, respectively] are depicted. The green line highlights the matrigel plugs,
differentiating them from the surrounding tissue, which was left in situ.
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typic switch, become hyperproliferative, and eventually obliterate
the vascular lumen (31, 35, 52). We have previously characterized
this group of angioproliferative lung vascular disorders as quasi-
malignant or precancerous (52), but features of immune dysregu-
lation as in autoimmune diseases are also present (53). For exam-
ple, angioproliferative PAH is associated with the limited form of
scleroderma, the so-called CREST syndrome, with systemic lupus
erythematosus, and with Sjo¨gren syndrome (30). In this regard, it is
interesting that IL-32 appears to regulate the production of NO,
which in turn has been implicated in the pathogenesis of PAH (40).
The presence of IL-32 in the angioproliferative plexiform lesions
of PAH is also consistent with the expression of this cytokine in
psoriatic skin lesions (11, 54), as increased angiogenesis is an
important feature of psoriasis. A similar comparison can be made
between plexiform lesions and the malignant brain tumor GBM
(31), and indeed, we found the abundance of IL-32 protein to be
increased in this highly vascularized tumor as well. This is in
agreement with another study that screened mRNA levels in this
neoplastic disease as well as in breast cancer, where mRNA for
IL-32 was also elevated (55).
Together with our previous results, these data suggested that
production of IL-32 in ECs was associated with activation and
proliferation of these cells. To determine whether IL-32 acts as
a causal nexus in the regulation of angioproliferation, we reduced
the abundance of this cytokine by siRNA in neonatal HUVECs and
adult pulmonary microvascular ECs and HAoECs, and we also
employed an in vivo and an in vitro angiogenesis assay. Our finding
that reduction of IL-32 arrested the proliferation of HUVECs is
consistent with data that IL-1b was found to possess angiogenic
properties in matrigel assays (42) and in tumors (56). Similar
properties have been described for IL-1a (49, 57), although it
should be noted that under different circumstances, IL-1a has
been shown to inhibit angiogenesis and tumor growth (58).
Whereas our in vitro proliferation assays showed that IL-32 plays
an important role in the proliferation of ECs, both the matrigel
studies as well as the coculture experiments demonstrated that an
IL-32 gradient did not simply attract ECs in a disorganized fashion.
Rather, IL-32 conferred a marked increase in the formation of new
EC tubes in the cocultures and new capillaries in the matrigel plugs.
The capillaries were functional, as they carried RBCs. In fact, at
FIGURE 6. Quantitative analysis of neocapillarization, lipoidosis, and influx of inflammatory cells into the matrigel plugs. After cutting and CD31 as
well as H&E staining, the slides of the matrigel plugs (n = 10/group) were assessed for the formation of capillaries (A, B) and for the surface area of these
capillaries (C), as well as for the presence of adipocytes (D) and WBCs (E). (A) Neocapillarization was determined by hand-counting and scored semi-
quantitatively with 0 representing no increase in neocapillarization, 1 a minimal increase, 2 a mild increase, 3 a moderate increase, and 4 a marked increase
in neocapillarization. Mean scores 6 SEM are shown. (B) The same slides were assessed by automated analysis using Aperio’s microvessel algorithm. The
graph depicts means of absolute numbers of microvessels per mm23 10266 SEM. (C) Computer-based analysis of the surface area of the capillaries in the
plugs. Means of the surface area of the microvessels on each slide6 SEM are shown. (D, E) The same semiquantitative scoring system as in (A) was used to
categorize the degree of lipoidosis (D) and inflammation (E). Mean scores 6 SEM are shown. *p , 0.05 for IL-32g versus vehicle, **p , 0.01 for IL-32g
or VEGF versus vehicle.
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100 ng/ml IL-32g was more efficient at achieving such neo-
capillarization than 25 ng/ml of the prototypical proangiogenic
mediator VEGF. These striking data establish IL-32 as a player on
the stages of PAH, neoplastic diseases, and wound healing.
The significance of the larger size of the IL-32–induced new
blood vessels compared with those induced by VEGF, as well as
the increase in lipoidosis that was also conferred by IL-32g, will
have to be determined. However, the latter observation is intriguing,
as one may infer an involvement of IL-32 in atherogenesis;
moreover, to our knowledge it represents the first indication for
a possible role of this cytokine in obesity. The absence of a dif-
ference in the influx of inflammatory cells between IL-32g and
FIGURE 7. Colocalization of integrin aVb3 with IL-32 and functional relevance of the interaction. (A–F) Representative optical sections acquired by
confocal microscopy of double immunofluorescence staining for IL-32 (red) and aVb3 (green). Nuclei are counterstained with DAPI (blue). (A) In lung
tissue from a representative control patient (without pulmonary vascular disease) single aVb3
+ cells are seen in the endothelial layer or perivascular region
of a pulmonary artery, indicated by double-headed arrow. One aVb3
+/IL-32+ cell (single-headed arrow) was found in the perivascular tissue (cytoplasmic
staining). (B–F) In lung tissue from a representative patient, aVb3 colocalized with IL-32 in the plexiform lesions. This colocalization occurred in the
nucleus, as indicated by arrowheads, as well as in the cytoplasm and the cell membrane, pointed to by arrows. Cells positive for IL-32 alone are indicated
with open arrows. (C) and (E) depict the regions enclosed by the dotted line in (B) and (D), respectively, at higher magnification. Original magnification
3400. Scale bar, 50 mm (n = 3 controls and 3 PAH patients). (G) HUVECs were pretreated with IFN-g (10 ng/ml) or vehicle for 24 h, followed by addition
of rIL-32g at the indicated concentrations (ng/ml) and/or the aVb3 inhibitor cyclo(Arg-Gly-Asp-D-Phe-Val) at 10 mM. Six hours thereafter, cells were lysed
and subjected to real-time PCR analysis. Fold changes in abundance of IL-8 mRNA normalized to 18S over control (which is set at 1) 6 SEM are depicted
(n = 3). *p , 0.05, ***p , 0.001 for IFN-g alone versus IL-32g plus IFN-g; #p , 0.05, ##p , 0.01 for IL-32g plus IFN-g versus IL-32g plus IFN-g plus
cyclo(Arg-Gly-Asp-D-Phe-Val).
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vehicle controls indicates that the angiogenic properties are not
dependent on intermediate chemokine release.
It is important to note that the manufacturer tests recombinant
human IL-32g for endotoxin by the Limulus amebocyte lysate
assay, which does not detect low amounts of LPS. It thus remained
unclear whether the reported effects of recombinant human
IL-32g would be identical in the complete absence of microbial
products; therefore, we generated a synthetic and completely en-
dotoxin-free IL-32g in order to eliminate the problems of microbial
contamination. The fact that synthetic IL-32g alone was inactive
at 150 and 500 ng/ml supports the pivotal concept that IL-32
requires cofactors such as TLR agonists or IFN-g for its biological
activities. Notwithstanding this fact, because the LPS-loaded
matrigel plugs did not differ from those loaded with vehicle, the
angiogenic effect was indeed due to IL-32, not the LPS contami-
nation of the recombinant protein preparation.
Importantly, our results not only confirm the recent finding that
IL-32 interacts with integrins, but they also demonstrate that the IL-
32–induced angiogenesis and cytokine production by ECs are at
least in part mediated by the integrin aVb3. We demonstrated
interaction of IL-32 with the aVb3 and aVb6 integrins and their
downstream signaling intermediates focal adhesion kinase and
paxillin (27). Integrins, including aVb3 (59), and focal adhesion
kinase (60, 61), contribute to angiogenesis and inhibitors of aVb3
inhibit this process (62); therefore, focal adhesion kinase may also
contribute to the proangiogenic properties of IL-32 and aVb3. The
high expression of the aVb3 integrin in lung endothelial cells in
a rat model of severe PAH has recently been reported (63). Fur-
thermore, our data suggest that IL-32 may use IL-8, u-plasminogen
activator, and/or MMP-9 while subduing the antiangiogenic prop-
erties of activin A, endostatin, and/or angiopoietin 2 to achieve its
proangiogenic programing of ECs.
Of note, although we did observe a mild trend toward an increase
in cell death in ECs when there was less IL-32, it should be stated
that changes in the abundance of IL-32 did not significantly affect
the regulation of apoptosis in these cells; for example, Bak-1,
Bcl-2, Bcl-xL, and lactate dehydrogenase remained unchanged.
We infer that at least in ECs, IL-32 has moderate effects on ap-
optotic programs at best. The effect of this cytokine on cell cycle–
related pathways was not part of this study, but it is an interesting
topic of further research.
Although not in ECs, the role of IL-32 in apoptosis and cancer
has been investigated previously; however, the results of these
studies are not homogeneous. On the one hand, IL-32g over-
FIGURE 8. IL-32g–induced in vitro EC tube formation requires functional aVb3. Human dermal fibroblasts were grown to confluence for 3 d, followed
by careful addition of HUVECs or HAoECs. Four hours later, treatment with the indicated concentrations of rIL-32g and/or 10 mM aVb3 inhibitor cyclo
(Arg-Gly-Asp-D-Phe-Val) was commenced. Treatment with recombinant human VEGF-165 (40 ng/ml) was used as internal assay control. On day 7 of
coculture, newly formed EC tubes were stained with Sambucus nigra lectin-FITC (green), nuclei were labeled with DAPI (blue), and the cells were then
examined microscopically. Five fields of view per condition were randomly chosen and photographed. (A) One represesentative image of five independently
performed HAoEC experiments is shown. (B and C) The number of visible branches in the cocultures containing HAoECs (B) or HUVECs (C) was counted
using ImageJ. Graphs illustrate the fold changes in the number of branches of the newly formed EC tubes over vehicle-stimulated cocultures (which are set
as 1). *p , 0.05, **p , 0.01, ***p , 0.001 for IL-32g or VEGF versus control. #p , 0.05, ##p , 0.01, ###p , 0.001 for IL-32g versus the aVb3
inhibitor. ¤p , 0.05, ¤¤p , 0.01, ¤¤¤p , 0.001 for IL-32g versus IL-32g plus the aVb3 inhibitor.
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expression resulted in reduced growth of melanoma and colon
cancer in mice and was associated with reduced expression of
antiapoptotic genes such as bcl2 and iap and an increase in cas-
pase3 and caspase9 (25). Other studies found that IL-32 con-
tributed to activation-induced cell death in normal T cells (2),
HEK cells, HeLa cells, and Mycobacterium tuberculosis–stimu-
lated THP-1 cells, and that IL-32g–induced apoptosis was de-
pendent on caspase-3 (5). In contrast, siIL-32 transfected into
bone marrow stromal cells conferred reduced apoptosis in ma-
lignant cells in chronic myelomonocytic leukemia (22), and it was
also shown to induce the proliferation of hematopoietic progenitor
cells (64). In pancreatic cancer, silencing of IL-32 suppressed
apoptosis and mRNA expression of bcl2, bclxl, and mcl1 (23).
Importantly, IL-32 was also demonstrated to be associated with
a more malignant and invasive phenotype of lung cancer, and IL-
32 levels correlated with those of IL-6, IL-8, and VEGF as well as
with a higher microvessel density in the tumors and a poor clinical
outcome (24). It appears likely that the overall effect of IL-32 on
apoptosis and cancer growth in experimental models depends on
the cell type in which this cytokine is (over)expressed or blocked
and whether other factors such as immune cells are a part of the
respective model.
Only a few studies have investigated IL-32 in the biology of the
endothelium—among them our own (4, 16) and some others (55,
64–67)—but these studies mainly focused on the role of IL-32
in endothelial inflammation. In addition to our own finding that
VEGF was unaffected by silencing of IL-32 in ECs, others have
reported the following data related to VEGF. Treatment of ECs
with VEGF did not change the abundance of IL-32 protein (4);
blockade of IL-32 by siRNA reduced the production of VEGF
from a human bone marrow stroma cell line (22); and the abun-
dance of IL-32 correlated with that of VEGF in lung cancer (24).
The last two studies as well as the data we present in this study
appear to contrast with the report of an increase in VEGF abun-
dance in human bronchial epithelial cells stimulated with cyto-
kines or rhinovirus after silencing of IL-32 (68). Supernatants
from these cells conferred enhanced angiogenesis in HUVECs
in vitro. This study was conducted in the setting of asthma, and IL-32
was silenced in epithelial cells, not ECs. Overall, the data obtained in
ECs in this study and in those of others favor the conclusion that the
angiogenesis driven by IL-32 is not mediated by VEGF.
In conclusion, we further expand the portfolio of properties of
IL-32, adding angiogenesis to the functions of this versatile
cytokine. Mechanistically, these proangiogenetic activities likely
use regulation of IL-8, MMP-9, activin A, and endostatin, but
not VEGF or TGF-b1. A second signal is required to render
cells responsive to exogenous IL-32, and IL-32-induced an-
giogenesis is at least in part dependent on the integrin aVb3.
Therefore, IL-32 emerges as a key nexus in endothelial cell
biology at which the pathways of inflammation and angiogen-
esis converge.
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